[Medication dependency and physician's role]

Area of Science:

• Pharmacology
• Public Health
• Epidemiology

Context:

• Benzodiazepine (BZD) use is common in patients with depression, anxiety, or agitation, despite recommendations for short-term use.
• Existing epidemiological studies in Germany leave many questions about BZD prescription patterns unanswered.
• The Federal Institute for Drugs and Medical Devices (BfArM) sought improved methods to monitor potentially dependency-inducing medications.

Purpose:

• To describe the methodology and present early findings of a pilot study tracking benzodiazepine prescriptions.
• To introduce a novel approach utilizing pharmacy data processing center information for medication risk assessment.
• To analyze prescription patterns using patient-years, a six-step risk scale, and diazepam-equivalence dose.

Summary:

• The pilot study analyzed data from a pharmacy processing center, employing patient-years and diazepam-equivalence dose for a comprehensive risk assessment.
• Approximately 35% of all benzodiazepine prescriptions identified in the study represented long-term treatment.
• The study found that in 80-90% of cases, the primary prescribing physician could ascertain the patient's risk level, even with multiple prescribers involved.

Impact:

• This study introduces a novel methodology for tracking benzodiazepine prescriptions, crucial for monitoring medications with dependency risks.
• The findings highlight a significant prevalence of long-term benzodiazepine treatment, underscoring the need for improved prescription monitoring.
• The developed risk assessment framework, utilizing pharmacy data, offers a scalable solution for public health surveillance of potentially addictive medications.